TransMedics Group Inc

TransMedics Group, Inc. (NASDAQ: TMDX) is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. 

As per our previous US Daily Report published on ‘TMDX’ on September 04, 2025, Kalkine provided a ‘Buy’ stance on the stock at USD 102.81 based on “price action, recent key business and financial updates, momentum in the stock over the last month, valuation upside, and technical indicators analysis” and the stock price has now moved up by ~30.65% since then and has attained resistance 1 and resistance 2.

Noted below are the details of support and resistance levels provided in our previous report:

Daily Chart

Considering a volatile market condition led by recent tariffs escalation from United States and subsequent retaliation, resistance 1 and resistance 2 attainment, recessionary fear, higher interest rate and geopolitical disruption, a ‘Sell’ rating is assigned to the ‘TMDX’ at the closing market price of USD 134.32, as of October 29, 2025.

Note: This report may be updated with details around fundamental and technical analysis, price chart in due course, as appropriate.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is October 29, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.